{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:18Z","timestamp":1792176378565,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-infectious uveitis (NIU) is a group of potentially vision-threatening diseases where timely management is critical, yet data on the timing and sequencing of therapeutic interventions remain limited. Here, we evaluated real-world patterns and delays in initiating key NIU therapies over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1218 patients with NIU referred to a hospital-based ophthalmology clinic in the North Denmark Region between 2010 and 2024 were included. The timing of treatment initiation with periocular corticosteroid injections, intravitreal dexamethasone implants (IDI), systemic prednisolone, or disease-modifying antirheumatic drugs (DMARDs), was analysed using cumulative incidence and incidence rates. Associations between patient characteristics and treatment initiation were assessed using Cox proportional-hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Systemic prednisolone and periocular corticosteroid injections were initiated rapidly, with most treatments administered within the first three months\u00a0after referral. IDI treatment\u00a0was\u00a0initiated later, with few patients receiving IDI during the first year. Initiation of DMARD therapy occurred gradually over the first year. At five years, cumulative incidences were: periocular corticosteroid injections 6.2% (95% CI: 4.9\u20137.9), IDI 2.6% (95% CI: 1.8\u20133.8), systemic prednisolone 11.3% (95% CI: 9.6\u201313.3), and DMARDs 4.1% (95% CI: 3.1\u20135.5). IDI use was more likely in intermediate, posterior, and panuveitis while DMARDs were more frequently\u00a0initiated in patients with bilateral disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemic and periocular corticosteroids\u00a0injections were used frequently and early, while IDI and DMARDs were introduced later. These findings may reflect the clinical characteristics of this cohort and potential barriers to timely corticosteroid-sparing therapies and highlight the importance of continued efforts to optimise timing of treatment in the management of NIU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04728-2","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:27:09Z","timestamp":1786472829000},"page":"2349-2354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of corticosteroid-sparing therapies in non-infectious uveitis: a population-based cohort study from Denmark"],"prefix":"10.1038","volume":"40","author":[{"given":"Viktor Skalkh\u00f8j","family":"Oest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9214-1504","authenticated-orcid":false,"given":"Bawan","family":"Halgurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-5365","authenticated-orcid":false,"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-0409","authenticated-orcid":false,"given":"Maria Vittoria","family":"Cicinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-7754","authenticated-orcid":false,"given":"Lasse J\u00f8rgensen","family":"Cehofski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"4728_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/09273949409057073","volume":"2","author":"VT Tran","year":"1994","unstructured":"Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm. 1994;2:169.","journal-title":"Ocul Immunol Inflamm"},{"key":"4728_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jama.2025.4358","volume":"334","author":"P Maghsoudlou","year":"2025","unstructured":"Maghsoudlou P, Epps SJ, Guly CM, Dick AD. Uveitis in adults: a review. JAMA. 2025;334:419\u201334. https:\/\/doi.org\/10.1001\/jama.2025.4358.","journal-title":"JAMA"},{"key":"4728_CR3","doi-asserted-by":"publisher","first-page":"1412930","DOI":"10.3389\/fopht.2024.1412930","volume":"4","author":"K Chauhan","year":"2024","unstructured":"Chauhan K, Tyagi M. Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. Front Ophthalmol. 2024;4:1412930.","journal-title":"Front Ophthalmol"},{"key":"4728_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. OPTH. 2019;13:1761.","journal-title":"OPTH"},{"key":"4728_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema. Ophthalmology. 2019;126:283.","journal-title":"Ophthalmology"},{"key":"4728_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Br\u00e9zin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis. Ophthalmology. 2018;125:757.","journal-title":"Ophthalmology"},{"key":"4728_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/biomedicines13020248","volume":"13","author":"S Yeo","year":"2025","unstructured":"Yeo S, Chung Y, Song JH, Bodaghi B, Touhami S. A meta-analysis of the efficacy and safety of the 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. Biomedicines. 2025;13:248.","journal-title":"Biomedicines"},{"key":"4728_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/jop.2012.0180","volume":"29","author":"CA Arcinue","year":"2013","unstructured":"Arcinue CA, Cer\u00f3n OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharm Ther. 2013;29:501\u201307. https:\/\/doi.org\/10.1089\/jop.2012.0180.","journal-title":"J Ocul Pharm Ther"},{"key":"4728_CR9","doi-asserted-by":"crossref","unstructured":"Sisk RA, Kiernan DF, Almeida D, Kolomeyer AM, Eichenbaum D, Kitchens JW Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients. J Ophthalmic Inflamm Infect. 2024;14:2-8.","DOI":"10.1186\/s12348-024-00427-9"},{"key":"4728_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/aos.17497","volume":"103","author":"B Halgurd","year":"2025","unstructured":"Halgurd B, Oest VS, Klefter ON, Subhi Y, Cicinelli MV, Wied J, et al. Cumulative incidence of macular edema in non-infectious uveitis indicates an early therapeutic window. Acta Ophthalmol. 2025;103:684\u201390.","journal-title":"Acta Ophthalmol"},{"key":"4728_CR11","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","volume":"122","author":"JH Kempen","year":"2015","unstructured":"Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122:1967\u201375.","journal-title":"Ophthalmology"},{"key":"4728_CR12","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2017.5103","volume":"317","author":"JH Kempen","year":"2017","unstructured":"Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317:1993\u20132005.","journal-title":"JAMA"},{"key":"4728_CR13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","volume":"116","author":"S Gangaputra","year":"2009","unstructured":"Gangaputra S, Newcomb CW, Liesegang TL, Ka\u00e7maz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188.","journal-title":"Ophthalmology"},{"key":"4728_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","volume":"125","author":"DA Jabs","year":"2018","unstructured":"Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018;125:193\u2013202.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04728-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04728-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04728-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:35Z","timestamp":1792173335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04728-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":14,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4728"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04728-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}